Cancer mutant genes in blood can be detected by the world’s most sensitive technology of 0.000000001% — using plasmonic nanomaterials for optical signal amplification, as developed by the Korea Institute of Materials Science (KIMS) (1^✔ ✔Trusted Source
Highly Sensitive 3D-Nanoplasmonic-Based Epidermal Growth Factor Receptor Mutation Multiplex Assay Chip for Liquid Biopsy

Go to source

).
The new technology achieved 96% diagnostic accuracy in detecting EGFR mutations in lung cancer patients (stages 1-4), offering a breakthrough in early cancer detection.

Previously utilized genetic analysis technologies had low analytical sensitivity to detect mutated genes compared to normal genes, making it difficult to accurately diagnose early-stage cancer patients.

In addition, it was difficult to establish a quick treatment strategy and apply it to screening tests due to the high cost and long time required for analysis and the need for special equipment.

To overcome these challenges, the research team developed a low-cost analysis technology that can analyze various cancer mutations within the target gene region within 1 hour with an ultra-high sensitivity of 0.000000001%.

This technology boasts the world’s highest level of sensitivity, which is 100,000 times better than the highest level of 0.0001% among reported technologies, and through this, the possibility of early diagnosis was confirmed using the blood of lung cancer patients.

96% Accurate Blood Test for Lung Cancer Mutations

This technology combines nanomaterial technology that significantly improves the fluorescence signal, and primer/probe design that suppresses the fluorescence signal of normal genes, amplifying only the fluorescence signal of cancer mutant genes.

This is because the accurate detection of even very small amounts of cancer-mutated genes requires not only strong fluorescent signal expression technology but also precise discrimination of fine fluorescent signals.

The team fabricated a biochip in the form of a microarray capable of simultaneously detecting three mutant genes of EGFR (deletion, insertion, and point mutations) on a plasmonic substrate made of three-dimensional, high-density gold nanostructures.

After evaluating the clinical performance of 43 domestic lung cancer patients (stages 1 to 4) and 40 normal groups, a clinical sensitivity of 93% for lung cancer patients and a clinical specificity of 100% for the normal group were confirmed.

This technology can play an important role in not only early diagnosis and detection of recurrence of cancer but also in monitoring treatment effectiveness and establishing personalized treatment plans.

In addition, liquid biopsy using blood is possible as an alternative to surgical tissue biopsy, reducing the burden on patients and simplifying the examination process.

It can also serve as a regular screening test, ultimately improving the quality of cancer management and treatment.

Senior researcher Min-young Lee said, “Because it is capable of comprehensively detecting various cancer mutations with the world’s highest level of ultra-high sensitivity, it can become a leading player in the early cancer diagnosis and treatment/recurrence monitoring market,” and added, “We expect that this will greatly improve the survival rate and quality of life of cancer patients.”

Reference:

1. Highly Sensitive 3D-Nanoplasmonic-Based Epidermal Growth Factor Receptor Mutation Multiplex Assay Chip for Liquid Biopsy
   – (http://dx.doi.org/10.1002/smsc.202400101)

Source-Eurekalert